C18orf32

Across TCGA pan-cancer cohorts, C18orf32 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of C18orf32’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where C18orf32 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C18orf32 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LUAD are the cancer types where C18orf32 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C18orf32 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.385	<.001	8	view →
PDAC	Male	II,III,IV	−1.014	<.001	6	view →
LUAD	Male	All	+0.328	<.001	5	view →
LSCC	All	All	+0.135	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

C18orf32–HNSC

Open the HNSC breakdown →